Boris Mankovsky

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Aruna D. Pradhan, Robert J. Glynn, Jean‐Charles Fruchart et al. · New England Journal of Medicine · 2022 · 638 citations · Full text

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

David C. Klonoff, Jing Wang, David Rodbard et al. · Journal of Diabetes Science and Technology · 2022 · 254 citations · Full text

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Matthias von Herrath, Stephen C. Bain, Bruce W. Bode et al. · The Lancet Diabetes & Endocrinology · 2021 · 163 citations · Full text

Inflammation, β-Cell Function, Diabetes Management +7

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Guntram Schernthaner, Naim Shehadeh, Anna Bazarova et al. · Cardiovascular Diabetology · 2020 · 152 citations · Full text